How big is Royalty Pharma Plc?

As of Jun 18, Royalty Pharma Plc has a market capitalization of 19,432.75 million, with net sales of 2,264.21 million and net profit of 1,768.17 million over the latest four quarters. Shareholder's funds are 6,946.58 million, and total assets amount to 18,222.72 million.

As of Jun 18, Royalty Pharma Plc has a market capitalization of 19,432.75 million, categorizing it as a Mid Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 2,264.21 million, while the sum of Net Profit for the same period is 1,768.17 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at 6,946.58 million and Total Assets at 18,222.72 million.

What does Royalty Pharma Plc do?

Royalty Pharma Plc invests in late-stage biopharmaceutical products and operates in the mid-cap market, with recent net sales of $568 million and a net profit of $433 million. The company has a market cap of approximately $19.43 billion, a P/E ratio of 11.00, and a dividend yield of 2.66%.

Overview:<BR>Royalty Pharma Plc is engaged in investing in late-stage biopharmaceutical products within the Pharmaceuticals & Biotechnology industry and operates in the mid-cap market.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 568 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 433 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 19,432.75 Million (Mid Cap)<BR><BR>Key Metrics:<BR>P/E: 11.00 <BR>Dividend Yield: 2.66% <BR>Debt Equity: 0.97 <BR>Return on Equity: 26.82% <BR>Price to Book: 2.91<BR><BR>Contact Details:<BR>Address: 110 East 59th Street, NEW YORK NY: 10022 <BR>Tel: 1 212 8830200 <BR>Website: https://www.royaltypharma.com

Should I buy, sell or hold Royalty Pharma Plc?

Who are in the management team of Royalty Pharma Plc?

As of March 2022, the management team of Royalty Pharma Plc includes Chairman and CEO Pablo Legorreta, Vice Chairman Christopher Hite, Directors M. Germano Giuliani and Rory Riggs, and Independent Directors Bonnie Bassler, Errol De Souza, and Catherine Engelbert. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Royalty Pharma Plc includes the following individuals:<BR><BR>- Mr. Pablo Legorreta, who serves as the Chairman of the Board and Chief Executive Officer.<BR>- Mr. Christopher Hite, who is the Vice Chairman of the Board and Executive Vice President.<BR>- Mr. M. Germano Giuliani, who is a Director.<BR>- Mr. Rory Riggs, who is also a Director.<BR>- Dr. Bonnie Bassler, who serves as an Independent Director.<BR>- Dr. Errol De Souza, who is another Independent Director.<BR>- Ms. Catherine Engelbert, who is also an Independent Director. <BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Is Royalty Pharma Plc technically bullish or bearish?

As of October 31, 2025, Royalty Pharma Plc shows a bullish technical trend, supported by daily moving averages and monthly indicators, despite some short-term weakness indicated by weekly metrics, while outperforming the S&P 500 in recent periods but underperforming over the longer term.

As of 31 October 2025, the technical trend for Royalty Pharma Plc has changed from mildly bullish to bullish. The daily moving averages indicate a bullish stance, while the monthly MACD and KST also support a bullish outlook. However, the weekly MACD and KST are mildly bearish, suggesting some short-term weakness. The Bollinger Bands are mildly bullish on a monthly basis, and Dow Theory shows a mildly bullish trend for both weekly and monthly periods. <BR><BR>In terms of performance, Royalty Pharma has outperformed the S&P 500 over the past week (1.56% vs. 0.71%), the past month (4.91% vs. 1.92%), and year-to-date (48.33% vs. 16.30%), but has underperformed over the longer three-year and five-year periods. Overall, the current technical stance is bullish, with a strong emphasis on the daily moving averages and monthly indicators.

Is Royalty Pharma Plc overvalued or undervalued?

As of November 14, 2025, Royalty Pharma Plc is considered fairly valued with a P/E ratio of 11, compared to its peer Incyte Corp.'s 22.95, despite recent strong performance and historical lagging long-term returns, suggesting a potential for recovery and growth.

As of 14 November 2025, the valuation grade for Royalty Pharma Plc moved from expensive to fair, indicating a more favorable assessment of its market position. The company appears to be fairly valued based on its current metrics, with a P/E ratio of 11, a Price to Book Value of 2.84, and an EV to EBITDA of 13.43. In comparison, its peer Incyte Corp. has a significantly higher P/E ratio of 22.95, suggesting that Royalty Pharma may offer a more attractive entry point for investors.<BR><BR>Despite recent strong performance, with a year-to-date return of 53.51% compared to the S&P 500's 14.49%, the company's long-term returns have lagged, particularly over the past three and five years. This contrast highlights the potential for recovery and growth in the near term, supporting the view that Royalty Pharma is fairly valued at present.